Patents by Inventor Christian Klein

Christian Klein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200231673
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: February 24, 2020
    Publication date: July 23, 2020
    Inventors: Oliver AST, Marina BACAC, Sabine IMHOF-JUNG, Christiane NEUMANN, Christian KLEIN, Stefan KLOSTERMANN, Michael MOLHOJ, Joerg Thomas REGULA, Wolfgang SCHAEFER, Pablo UMANA
  • Publication number: 20200223925
    Abstract: The present invention relates to tumor targeted superagonistic antigen binding molecules capable of multivalent binding to CD28, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.
    Type: Application
    Filed: December 19, 2019
    Publication date: July 16, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stephan GASSER, Guy GEORGES, Thomas HOFER, Christian KLEIN, Jenny Tosca THOM, Pablo UMAÑA
  • Publication number: 20200216554
    Abstract: Herein are provided bispecific anti-human CD20/human transferrin receptor antibodies and methods of using the same.
    Type: Application
    Filed: March 18, 2020
    Publication date: July 9, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Harald DUERR, Sebastian FENN, Ulrich GOEPFERT, Sabine IMHOF-JUNG, Christian KLEIN, Laurent LARIVIERE, Michael MOLHOJ, Joerg Thomas REGULA, Petra RUEGER, Wolfgang SCHAEFER
  • Publication number: 20200199234
    Abstract: The present invention relates to tumor targeted bispecific agonistic antigen binding molecules characterized by monovalent binding to CD28, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.
    Type: Application
    Filed: December 19, 2019
    Publication date: June 25, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Guy GEORGES, Thomas HOFER, Ralf HOSSE, Christian KLEIN, Ekkehard MOESSNER, Johannes SAM, Pablo UMAÑA, Jenny THOM, Stephan GASSER, Jean-Baptiste VALLIER, Tanja FAUTI
  • Publication number: 20200197492
    Abstract: The present invention provides combinations of (a) an immunoconjugate comprising a first antibody engineered to have reduced effector function and an effector moiety, and (b) a second antibody engineered to have increased effector function, for use in treating a disease in an individual in need thereof. Further provided are pharmaceutical compositions comprising the combinations, and methods of using them.
    Type: Application
    Filed: March 2, 2020
    Publication date: June 25, 2020
    Applicant: Roche Glycart AG
    Inventors: Christian GERDES, Christian KLEIN, Valeria G. NICOLINI, Pablo UMANA
  • Publication number: 20200199215
    Abstract: The present invention relates to the combination therapy of an antibodies that binds to human angiopoietin 2 (ANG-2) with a CD40 agonist.
    Type: Application
    Filed: February 28, 2020
    Publication date: June 25, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Christian Klein, Markus Thomas, Alfred Zippelius, Philipp Mueller
  • Publication number: 20200190206
    Abstract: The invention relates to new bispecific antigen binding molecules, comprising at least one antigen binding domain capable of specific binding to 4-1BB, at least one moiety capable of specific binding to a target cell antigen, and a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: June 19, 2019
    Publication date: June 18, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Claudia FERRARA KOLLER, Christina CLAUS, Christian KLEIN, Pablo UMAÑA, Wei XU
  • Publication number: 20200190207
    Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP) comprising FAP clone 212 or variants thereof, and (b) at least one antigen binding domain capable of specific binding to CD40, and to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: September 30, 2019
    Publication date: June 18, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Peter BRUENKER, Harald DUERR, Christian KLEIN, Pablo UMANA, Alexander BUJOTZEK, Joerg ZIELONKA, Christine TRUMPFHELLER, Moritz RAPP, Marine LE CLECH
  • Publication number: 20200188526
    Abstract: The invention provides compositions and methods for treating cancer, the method comprising administering an IL-2 immunoconjugate, a CD40 agonist and optionally a PD-1 axis binding antagonist.
    Type: Application
    Filed: October 8, 2019
    Publication date: June 18, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Christian KLEIN, Valeria G. NICOLINI, Pablo UMAÑA
  • Patent number: 10683345
    Abstract: The present invention relates to bispecific antibody against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2) of human IgG1 or IgG4 subclass with mutations I253A, H310A, and H435A, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: June 16, 2020
    Assignee: Roche Glycart AG
    Inventors: Harald Duerr, Frank Herting, Christian Klein, Joerg Thomas Regula, Matthias Rueth, Kay-Gunnar Stubenrauch
  • Patent number: 10683369
    Abstract: The invention relates to new antibodies against BCMA, their manufacture and use.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: June 16, 2020
    Assignee: EngMab Sàrl
    Inventors: Minh Diem Vu, Klaus Strein, Oliver Ast, Marina Bacac, Camille Delon, Lydia Jasmin Hanisch, Anne Freimoser-Grundschober, Christian Klein, Ekkehard Moessner, Samuel Moser, Pablo Umana, Tina Weinzierl
  • Patent number: 10684764
    Abstract: A technique is described herein for helping a user move a source object that appears on a user interface presentation to a target destination. The technique involves performing semantic analysis on both the source object and at least one candidate target destination. The semantic analysis yields a score that reflects the relationship between the source object and the candidate target destination. The technique then presents a representation of the candidate target destination that is visually enhanced to an extent that is dependent on its output score. The technique then allows the user to move the source object to a representation of a selected target destination, whereupon it becomes associated with the target destination. The technique can produce the enhanced representation by changing a characteristic of an on-screen target identifier (that already exists on the user interface presentation), or by displaying a transient target identifier.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: June 16, 2020
    Assignee: Microsoft Technology Licensing, LLC
    Inventors: Christian Klein, Gyancarlo Garcia Avila, Jesse Matthew Liston, Sophors Khut
  • Publication number: 20200171153
    Abstract: The present invention is directed to the combination therapy of an anti-CD20 antibody with a BTK inhibitor for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with a type I anti-CD20 antibody or an afucosylated humanized B-Ly1 antibody and a BTK inhibitor.
    Type: Application
    Filed: November 11, 2019
    Publication date: June 4, 2020
    Inventors: Christian Klein, Toshio Yoshizawa, Tomoko Yasuhiro
  • Publication number: 20200172633
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells comprising a common light chain. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: August 15, 2019
    Publication date: June 4, 2020
    Inventors: Christian KLEIN, Ekkehard MOESSNER, Ralf HOSSE, Peter BRUENKER, Pablo UMANA, Christiane NEUMANN
  • Publication number: 20200174660
    Abstract: The disclosed technologies address various technical and user experience problems by augmenting the functionality provided by virtual on-screen trackpads without requiring users to switch between modes. In this way, users can access extended functionality without interfering with expected traditional trackpad functionality (e.g. moving a cursor, clicking, and scrolling). In particular, technologies are disclosed for modeless digital pen input to a virtual trackpad, modeless gestures for summoning user interfaces, modeless gestures utilizing position relative to adjacent user interfaces, and modeless cursor control and interaction with virtual touch targets.
    Type: Application
    Filed: December 3, 2018
    Publication date: June 4, 2020
    Inventors: Christian KLEIN, Andrew Stuart GLASS
  • Publication number: 20200174566
    Abstract: The disclosed technologies address various technical problems, including improving human-computer interaction, by augmenting the functionality provided by user input devices using a digital glove. For example, a digital glove can be utilized to provide pressure sensitivity for non-pressure sensitive touchscreen devices, attribute input made with a digital pen to a user wearing the digital glove, augment the functionality provided by mice and other types of handheld user input devices, augment the functionality provided gaze tracking systems, improve camera-based motion tracking systems, and to augment the functionality provided by speech recognition systems.
    Type: Application
    Filed: December 3, 2018
    Publication date: June 4, 2020
    Inventors: Christian KLEIN, Andrew Stuart GLASS, Sang Ho YOON
  • Publication number: 20200174653
    Abstract: The disclosed technologies address various technical and user experience problems by augmenting the functionality provided by virtual on-screen trackpads without requiring users to switch between modes. In this way, users can access extended functionality without interfering with expected traditional trackpad functionality (e.g. moving a cursor, clicking, and scrolling). In particular, technologies are disclosed for modeless digital pen input to a virtual trackpad, modeless gestures for summoning user interfaces, modeless gestures utilizing position relative to adjacent user interfaces, and modeless cursor control and interaction with virtual touch targets.
    Type: Application
    Filed: December 3, 2018
    Publication date: June 4, 2020
    Inventors: Christian KLEIN, Andrew Stuart GLASS
  • Publication number: 20200172591
    Abstract: The present invention generally relates to fusion proteins of immunoglobulins and interleukin-2 (IL-2). In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: February 5, 2020
    Publication date: June 4, 2020
    Applicant: Roche Glycart AG
    Inventors: Ralf Hosse, Christian Klein, Ekkehard Moessner, Laurence Bernard Peterson, Pablo Umana, Linda Wicker
  • Publication number: 20200172627
    Abstract: The present invention relates to methods of treating a disease, and methods for reduction of cytokine release associated with the administration of a T-cell activating therapeutic agent. The present invention further relates to combination treatment methods of treating a disease and antibodies for the use in such methods.
    Type: Application
    Filed: November 22, 2019
    Publication date: June 4, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina BACAC, Sara COLOMBETTI, Christian KLEIN, Johannes SAM, Pablo UMAÑA
  • Publication number: 20200174567
    Abstract: The disclosed technologies address technical problems, including improving human-computer interaction, by augmenting the functionality provided by non-digital objects using a digital glove. To provide this functionality, a machine learning model is trained using sensor data generated by sensors in a digital glove and data generated by a user input device while the digital glove is utilized to manipulate an object like a user input device. Once trained, the machine learning model can take sensor data generated by a digital glove while manipulating a non-digital object and generate virtual user input device data that can be utilized to control a host computer. A digital glove can also be utilized to perform selection operations using non-digital objects when pressure data generated by one or more of the pressure sensors in the digital glove indicates that pressure was exerted at a finger of the digital glove in excess of a threshold value.
    Type: Application
    Filed: December 3, 2018
    Publication date: June 4, 2020
    Inventors: Christian KLEIN, Andrew Stuart GLASS, Sang Ho YOON